Adverse skin reactions associated with tumor therapy
Conditions
Interventions
Treatment Group:Topical Effective Skin Care Products + Standard Treatment
Control Group:Standard Treatment
Sponsors
China-Japan Friendship Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: Patients with malignant tumors with a clear pathologic diagnosis. (2) Undergoing treatment with EGFRIs. (3) Presenting with dry skin associated with EGFRIs therapy. (4) Age 18-85 years old, gender is not limited. (5) Willing to accept the treatment, observation and various examinations, good compliance, and must sign the informed consent before enrollment. (6) Subjects agree not to participate in other intervention studies during the treatment period.
Exclusion criteria
Exclusion criteria: (1) Those with severe bleeding or systemic infections that have not been controlled, or those with suppurative and chronically infected wounds that have not healed. (2) Those with a previous history of allergy to topical medications, or allergic constitution. (3) Combined severe cardiovascular system complications, cerebrovascular system complications, active hepatitis, severe liver and kidney function abnormalities. (4) Patients who have participated in other drugs subjected to trials within the past 4 weeks, or those who are currently participating in clinical trials. (5) Any unstable condition or condition that may jeopardize the safety of the patient and his/her compliance with the study, such as mental retardation, schizophrenia and other severe mental illnesses, inability to understand, read and fill out the patient self-assessment scale, and inability to cooperate with the treatment and examination. (6) Have developed intestinal obstruction that cannot be treated with oral medication and requires intravesical high-energy nutrition. (7) Suffering from severe malabsorption or other diseases that affect the absorption of the gastrointestinal tract. (8) Those who are judged by the investigator to be unsuitable for participation in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Evaluation of the degree and extent of skin lesion improvement; | — |
Secondary
| Measure | Time frame |
|---|---|
| Improvement in quality of life (DLQI score); | — |
Countries
CHINA
Contacts
Public ContactCUI YONG
China-Japan Friendship Hospital
Outcome results
None listed